复宏汉霖(02696.HK)：HLX22联合HLX87乳腺癌临床研究完成首例患者给药

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has announced the completion of the first patient dosing in a Phase 2/3 clinical study for HLX22, a humanized anti-HER2 monoclonal antibody injection, in combination with HLX87, a targeted HER2 antibody-drug conjugate, for the treatment of HER2-positive recurrent or metastatic breast cancer patients in mainland China [1] Group 1 - The clinical study is focused on HER2-positive recurrent or metastatic breast cancer patients [1] - HLX22 is a restructured humanized anti-HER2 monoclonal antibody injection [1] - HLX87 is a targeted HER2 antibody-drug conjugate [1]